CN110898053A

CN110898053A - Application of monascin C in preparation of fat-reducing product

Info

Publication number: CN110898053A
Application number: CN201911340509.XA
Authority: CN
Inventors: 陈勉华; 王小璐; 王路; 张妍; 张琴; 肖金平; 樊弘; 王玉荣; 李鹏; 奚星平
Original assignee: Tianjin University of Science and Technology
Current assignee: Tianjin University of Science and Technology
Priority date: 2019-12-23
Filing date: 2019-12-23
Publication date: 2020-03-24
Anticipated expiration: 2039-12-23
Also published as: CN110898053B

Abstract

The invention provides an application of monascin C (monascinol) in preparation of a fat-reducing product. The lipid-reducing preparation comprises a lipid-reducing functional food for preventing or improving a sub-health state associated with obesity in an individual or a lipid-reducing pharmaceutical product for preventing or treating a disease associated with abnormal lipid metabolism in an individual. According to the scheme, the monascin C has the novel functions of remarkably reducing blood fat, controlling weight gain and inhibiting body fat accumulation; and has reduced cytotoxicity, and higher safety as a lipid-lowering product.

Description

Application of monascin C in preparation of fat-reducing product

Technical Field

The invention relates to application of monascin C, in particular to application of monascin C in preparation of a fat-reducing product.

Background

The lipid is one of the components of cell membrane and lipoprotein, mainly comprises cholesterol and triglyceride, is not only used for synthesizing sterol substances in vivo, but also can provide energy required by metabolism for human body. Hyperlipidemia may be caused by excessive lipid accumulation in a human body. Hyperlipidemia (Hyperlipdemia, HLP) is a metabolic disease with obviously increased levels of Total Cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in human plasma and low level of high-density lipoprotein cholesterol (HLD-C), and is a key factor for inducing cardiovascular diseases such as atherosclerosis, non-alcoholic fatty liver and the like.

Cholesterol is one of the major components of the cell membrane of an organism and is also the precursor of all steroid hormones, and is vital for vital activities. The liver is the core organ of cholesterol metabolism, which relies primarily on the transport of cholesterol by a variety of apolipoproteins with peripheral tissues. Normally, synthesis, absorption and excretion of cholesterol are kept in a steady state, and excessive synthesis or absorption of cholesterol causes disorder of cholesterol metabolism to cause hyperlipidemia. Triglyceride is formed by esterification of glycerol and fatty acid, is the main component of blood fat, and is also an important energy supply substance for organisms. Triglycerides are produced in two main ways: the phosphatidic acid pathway and the monoglyceride pathway. Triglyceride is synthesized in liver cells mainly through a phosphatidic acid pathway, and then the triglyceride is synthesized with apolipoprotein, cholesterol and the like to form very low density lipoprotein, and the very low density lipoprotein is transported to extrahepatic tissues for storage or utilization through blood circulation. Triglyceride accumulation in the liver, resulting in non-alcoholic fatty liver disease (NAFLD), occurs when triglyceride synthesis in hepatocytes increases, secretion of very low density lipoproteins decreases, and fatty acid oxidation capacity decreases. The prevalence of NAFLD is closely related to obesity. Intervention prevention from the early stages of development of NAFLD through dietary adjustments is currently an important link in preventing further deterioration of NAFLD. The monoglyceride pathway is mainly carried out in the small intestine, and fat ingested by the human body is primarily digested by the oral cavity and the stomach, and is hydrolyzed into glycerol and fatty acid by pancreatic lipase in the small intestine, and then is absorbed by the human body. Excessive intake of triglycerides can cause obesity, and pancreatic lipase inhibitors can inhibit pancreatic lipase activity in the small intestine and reduce lipid absorption to some extent, and are one of effective ways for drug treatment of obesity.

Triglyceride and cholesterol are important components of human lipid substances, and excessive storage can cause the occurrence risks of obesity, cardiovascular diseases, diabetes and the like to rise dramatically. Hyperlipidemia caused by obesity can cause arteriosclerosis and increase the risk of cardiovascular diseases; fatty liver is more likely to appear in obese people; in obese people, excess fat in the body can also be deposited in the respiratory tract, affecting respiratory function and exacerbating the symptoms of asthmatic patients. Obesity is an important "pivot" for the development of cardiovascular diseases, diabetes, asthma, nonalcoholic fatty liver, osteoarthritis, and cancer.

The application of Monascus (Monascus) in Chinese fermented foods has been in history for thousands of years, Monascus pigment is a secondary metabolite of Monascus, and the types of Monascus pigment with clear and complete structure analysis data recorded in the literature exceed 60.

Japanese invention patent JP2008-56618A in 2008 reports a monascus yellow pigment named Monascinol for the first time to have anti-inflammatory and anti-cancer functions.Wt. Taiwan patent TW1437001B in 2014, China, reports a monascus yellow pigment named Monascus pulin (TW1437001B) which can inhibit 5 α -reductase activity, reduce the production of male hormone dihydrotestosterone and treat male hormone disorder related diseases.

The pigments Monascuspilin and Monascinol have not been found to have the effects of reducing blood fat, controlling weight gain and inhibiting body fat accumulation.

Disclosure of Invention

The invention provides application of monascin C (monascinol) in preparation of a fat-reducing product. The monascin C has effects of reducing blood lipid, controlling weight gain, and inhibiting body fat accumulation.

In the scheme of the invention, monascin C (Monascinol) and pigment Monascus spiloid and Monascinol have the same structure and are the same substance, and in the application, the applicant is named as monascin C (Monascinol), and finds that the monascin C (Monascinol) has the functions of obviously reducing blood fat, controlling weight gain and inhibiting body fat accumulation.

The invention provides an application of monascin C in preparation of a fat-reducing product.

In one embodiment of the invention, the fat-reducing preparation comprises a fat-reducing functional food.

Further, the lipid-lowering functional food is used for preventing or improving the sub-health state of an individual associated with obesity.

In another embodiment of the invention, the lipid-reducing preparation comprises a lipid-reducing pharmaceutical product.

Further, the lipid-lowering drug is used for preventing or treating a disease associated with abnormal lipid metabolism in an individual.

Further, the subject's disease associated with abnormal lipid metabolism includes one or more of non-alcoholic fatty liver disease, cardiovascular disease, diabetes and asthma.

Further, the lipid-lowering drug may be formulated in the form of hard capsules, soft capsules, tablets, granules, powders, suspensions, syrups, oral liquids or injections.

The fat-reducing medicine can also comprise pharmaceutically acceptable excipient, auxiliary materials and the like according to different selected dosage forms.

Further, in the embodiment of the present invention, the lipid-lowering drug is a unit preparation. For example, the unit preparation contains 50-200mg of monascin C. Of course, the amount of monascin C may be appropriately adjusted depending on the subject to be administered, as long as the prevention or treatment of the disorder associated with abnormal lipid metabolism in the individual can be achieved.

In the present embodiment, the amount of monascin C in a unit formulation is the amount of the active ingredient in a single administration of the medicament for the weight of a typical adult. The unit preparation is a preparation of effective components required by one-time administration, and common unit preparations are a unit (tablet) tablet, a unit (needle) injection or a powder injection and the like. The amount of drug required for a single administration to a patient can conveniently be calculated by multiplying the weight of the patient by the unit weight dose required for a single administration to the patient. For example, in the process of preparing a medicament, it is generally considered that the weight of an adult is 50-90kg, and the dosage can be determined by equivalent dose conversion between unit weight doses of experimental animals and humans. For example, the determination can be made by referring to the guidelines proposed by the drug administration such as FDA and SFDA (Huang-Ji Han, et al, "equivalent dose conversion between animals and humans in pharmacological tests", Chinese clinical pharmacology and therapeutics, 2004 Sep; 9(9): 1069-. In the embodiment of the present invention, the dose of human and hamster can be converted by using a coefficient of conversion of the body surface area of human and hamster to 0.12.

Monascin C in the present invention can be obtained by the method for obtaining monascuspiloid described in the invention patent TW1437001 of taiwan in china in 2014 or the method for obtaining Monascinol described in JP 2008-56618A.

Alternatively, it can be obtained by the following method for preparing monascin C, comprising:

1) preparing a solid culture medium: soaking rice in water, and sterilizing to obtain the solid culture medium;

2) preparing a seed solution: activating the monascus, inoculating the activated monascus to a seed liquid culture medium for culture, and obtaining a seed liquid;

3) fermentation: injecting the seed liquid into the solid state fermentation culture medium for fermentation to obtain fermented rice, namely red yeast rice;

4) and (3) extraction of monascin C: drying and crushing the red yeast rice, extracting by using ethanol, and separating an extracting solution by using high performance liquid chromatography to obtain the monascin C.

In the above method, there is no particular limitation on the source of the rice, which may be, for example, ordinary commercially available rice.

The monascus used may be the monascus described in taiwan patent TW1437001 in china 2014. Or Monascus purpureus went deposited in China general microbiological culture Collection center (CGMCC) by the applicant at 2019, 20 months and 9 months at the location of No. 3 Hospital No.1, Kyowa, Chaoyang, Beijing, with the collection number of CGMCC No. 18578.

In the case of monascus preparation with CGMCC No.18578, in order to increase the yield, the preparation of monascin C can also be carried out according to the following steps:

3) fermentation: and (3) mixing the seed liquid according to the proportion of 1: injecting 5-10L/kg of the fermented rice into the solid fermentation culture medium for fermentation to obtain fermented rice, namely red yeast rice;

4) and (3) extraction of monascin C: drying and crushing the red yeast rice, and extracting by using 50-80% ethanol, wherein the weight ratio of the red yeast rice to the ethanol in the extraction is controlled to be 1: and 5-20, and separating the extracting solution by using high performance liquid chromatography to obtain the monascin C.

In another embodiment of the present invention, the method for preparing monascin C comprises the following steps:

1) preparing a solid culture medium: spreading wet rice formed by soaking the rice in water in a conical flask, and sterilizing to obtain a solid fermentation culture medium;

2) preparing a seed solution: activating the monascus by using an activation medium, and inoculating the monascus to a seed liquid culture medium for culture to prepare a monascus seed liquid;

3) fermentation: filtering the monascus seed liquid to remove mycelia, and mixing the monascus seed liquid without mycelia according to a ratio of 1: injecting 5-10L/kg of the fermented rice into the solid fermentation medium for fermentation to obtain fermented rice, namely red yeast rice;

4) and (3) extraction of monascin C: drying and crushing red yeast rice obtained after fermentation, and extracting by using 50-80% ethanol, wherein the weight ratio of the red yeast rice to the ethanol in the extraction is controlled to be 1: and 5-20, and separating the extracting solution by using high performance liquid chromatography to obtain the monascin C.

Further, the proportion of the rice and the water in the soaking process in the step 1) is 1:1kg/L, and the rice is soaked for 4-24h at room temperature.

Further, the activation temperature of the monascus in the step 2) is 25-35 ℃, and the monascus is activated and cultured for 2-5 days. Further, in the step 2), the activation medium is a wort slant medium.

The wort slant medium is a medium conventional in the art and is commercially available. Can also be prepared according to the following steps: slightly pulverizing barley malt, weighing 250.0g, adding 1L water, heating in 60 deg.C constant temperature water bath for 4 hr, filtering, adding water, diluting to 12 ° Brix, adding 3.0g agar, and sterilizing at 121 deg.C and 0.1MPa for 20 min.

Further, the activated monascus purpureus in the step 2) is inoculated into the seed liquid culture medium and cultured in a constant temperature shaking table, the temperature of the shaking table is controlled to be 25-35 ℃, the rotation speed of the shaking table is 150-.

The seed liquid culture medium is a culture medium which is conventional in the field and can be purchased. Can also be prepared according to the following formula, wherein the seed liquid culture medium comprises 6.0 parts by weight of glucose, 2.0 parts by weight of peptone and 1.0 part by weight of NaNO₃1.0 part of KH₂PO₄0.5 part of MgSO₄And 100 parts of water. For example, 6.0g of glucose, 2.0g of peptone and 1.0g of NaNO₃、1.0gKH₂PO₄、0.5gMgSO₄Dissolving in 100mL water, packaging into 250mL conical flask, sealing with 8 layers of gauze and kraft paper, and sterilizing at 121 deg.C and 0.1MPa for 20 min.

Further, the fermentation temperature in the step 3) is 25-35 ℃, and the fermentation time is 10-25 days.

And 4) separating the extracting solution by using high performance liquid chromatography to obtain the Monascin C, wherein Monascin (MS) is obtained from the extracting solution. The applicant has found that both MS and MC are present in the extract, and they can be separated from the extract by conventional techniques, for example, collecting MS and MC separately during HPLC separation according to their peak times, which can be realized by those skilled in the art.

Further, MS can be converted to MC by the means of formula 1; the method for preparing MS provided by the application can also comprise a step 5) of converting MS obtained from the extracting solution into MC so as to further improve the yield of MC,

the MS is further converted into MC according to the formula 1, and the yield of MC produced by fermenting monascus of the application can be further improved.

The scheme of the invention has the following advantages:

1) the monascin C is found to have the functions of obviously reducing blood fat, controlling weight gain and inhibiting body fat accumulation for the first time; and has reduced cytotoxicity, and higher safety as a lipid-lowering product.

2) The present invention provides the use of monascin C in the preparation of a lipid-lowering functional food for preventing or improving the sub-health status associated with obesity in an individual, such as a sub-health population in need of weight management including adults and adolescents.

3) The invention also provides the application of the monascin C in preparing fat-reducing products including fat-reducing medicines, which is used for preventing or treating individual diseases related to abnormal lipid metabolism, including non-alcoholic fatty liver, cardiovascular diseases, diabetes and asthma; it can also be used for preventing and treating a series of diseases closely related to obesity, such as diabetes, cardiovascular diseases, asthma and osteoarthritis.

Drawings

FIG. 1A shows HepG2 cells before oleic acid addition and FIG. 1B shows HepG2 cells lipid packing after oleic acid addition.

FIG. 2 shows the effect of different dosages of MC and MS on the survival of HepG2 cells after oleic acid modelling.

FIG. 3 shows the effect of different MC administration concentrations on the intracellular TG content of HepG2 after oleic acid modelling.

FIG. 4 shows the effect of MC and MS on the intracellular TG content of HepG2 after oleic acid modelling.

FIG. 5A is a graph of intracellular lipid packing of oleic acid molding HepG 2; FIG. 5B is a graph of intracellular lipid packing in MS group HepG 2; fig. 5C is a graph of intracellular lipid packing for MC group HepG 2.

FIG. 6 shows the inhibitory activity of MC on pancreatic lipase as a function of concentration.

FIG. 7A is a graph showing the results of inhibition ratios of different addition sequences of MS (Monascin ) reactants; FIG. 7B is a graph showing the results of inhibition rates of AK (Ankaflavin ) reactant addition sequences; FIG. 7C is a graph showing the results of inhibition ratios for MC (monascin C, Monascinol) in different addition sequences.

FIG. 8 shows the Lineweaver-Burk curve for MC.

Fig. 9A to 9C show the results of the liver tissue sections for each hamster under 100 x-ray, and fig. 9A to 9C show the results of the liver tissue sections for each hamster under 400 x-ray.

Fig. 10A to 10C show the results of the examination under 100 x-ray, and fig. 10A to 10C show the results of the examination under 400 x-ray, for each hamster.

Figure 11 shows the LCMS primary positive ion spectrum of MC.

FIG. 12 shows MC¹H-NMR spectrum.

FIG. 13 shows MC¹³C-NMR spectrum.

Detailed Description

HepG2 cells in the examples of the present application were purchased from Synergic cell resources center (resource No: 3111C0001CCC000035), and various reagents used in the experimental procedures were conventional reagents and commercially available. Monascin C (Monascinol, abbreviated as MC) can be prepared by the method of JP2008-56618A or TW 1437001B. Monascin (MS) can be prepared by the method in JP 2008-56618A. Monascin C (MC for short) and Monascin (MS for short) can also be prepared using Monascus (Monascus sp) described in this application. The Monascus purpureus (Monascus sp) is Monascus purpureus, which is preserved in China general microbiological culture Collection center (CGMCC for short) in 2019, 9 months and 20 days, and the preservation number is CGMCC No. 18578. The raw material is rice which is commonly purchased and obtained, and all components in the culture medium are reagents which are conventional in the field and can be purchased commercially.

Example 1 cytotoxicity of Monascus flavin C

1) Oleic acid molding HepG2 cell

Taking HepG2 cells with good growth state as 2 x 10⁵one/mL, 1mL per well, was inoculated into 6-well culture plates. And when the anchorage rate of the cells reaches 80% -90%, discarding the culture medium. Setting a blank group and a model group, adding complete culture medium into the blank group, adding 0.3mmol/L oleic acid inducing solution diluted with the complete culture medium into the model group, adding 2mL per hole, culturing for 24h, and observing the accumulation condition of lipid droplets in cells by oil red O staining.

The blank group of cells is fusiform in shape, the edges of the cells are clear, and no obvious lipid droplets are accumulated in the cells; adherent HepG2 cells added with 2 mL0.3mmol/L oleic acid induction liquid have no obvious proliferation damage after 24h of incubation culture, and compared with a blank group, the cell edges can see obvious red fat drops around the cell nucleus, the cell outline is clearer, which indicates successful modeling, and referring to FIG. 1, FIG. 1A-FIG. 1B show the influence of the addition of oleic acid on the lipid accumulation of HepG2 cells (inverted microscope X400).

2) Cytotoxicity test of Monascinol (MC) and Monascin (MS) on oleic acid molded HepG2 cell

a. Taking HepG2 cells with good growth state as 5 x 10⁴Each well was inoculated at 100. mu.L per well in a 96-well plate. And when the anchorage rate of the cells reaches 80% -90%, discarding the culture medium.

b. MS and MC were dissolved in DMSO to prepare a 5mg/mL stock solution, which was stored at-20 ℃. 5mg/mL of the mother liquor was diluted with complete medium containing 0.3mmol/L oleic acid to the desired concentration of MS or MC samples (2, 4, 6, 8, 10, 12. mu.g/mL) to ensure a final DMSO concentration of 0.5% in each sample.

c. A molding set and a drug adding set are arranged,

on day 1 (after discarding the medium), 200. mu.L of complete medium containing 0.3mmol/L oleic acid was added to the molded HepG2 cells; to the drug-added HepG2 cells, 200. mu.L of complete medium containing 0.3mmol/L oleic acid and the above-mentioned MS or MC samples at different concentrations were added.

After 24h, the survival rate of HepG2 cells in each group was tested according to the MTT test method.

d. As shown in FIG. 2, when the concentration of MS administered was 10. mu.g/mL or more, the cell survival rate was only 36.7%, cytotoxicity began to appear, and the cells died in large amounts. The cell survival rate of MC at 12 μ g/mL is 66.7%, which is significantly less than the cytotoxicity of MS at the same concentration.

Example 2 Effect of different dosing of Monascus flavins C on cellular triglyceride levels

The experiments were performed as follows:

a. selecting good HepG2 cells according to 2 x 10⁵And (4) inoculating 1mL of the cells per well into a 6-well culture plate for 12 hours, and removing the culture medium after the cells are attached to the wall.

b. Discarding the culture medium, setting a blank group, building a module group and adding the medicine group.

Blank control group: 2mL of complete medium was added;

the oleic acid molding group: adding 2mL of complete culture medium containing 0.3mmol/L of oleic acid;

MC low dose group: adding 2mL of complete culture medium containing 0.3mmol/L of oleic acid and 2 mu g/mL of monascin C;

dose groups in MC: adding 2mL of complete culture medium containing 0.3mmol/L of oleic acid and 4 mu g/mL of monascin C;

MC high dose group: 2mL of complete medium containing oleic acid 0.3mmol/L and monascin C8. mu.g/mL were added.

After completion of the administration, each group of cells was cultured for 24 hours, and each group of cells was collected, and the content of triglyceride in each group of HepG2 cells was measured using a triglyceride kit (beijing prilley gene technology, ltd).

c. The results are shown in FIG. 3, where different letters indicate significant differences from the blank group ratio, P < 0.01.

As can be seen from FIG. 3, the TG content in the molding group was significantly increased (P < 0.01) compared to the blank group, and the intracellular TG content reached 3.2 times that in the normal group, indicating successful molding. Compared with the modeling group, the low, medium and high dosages of MC can obviously reduce the content of TG in cells (P is less than 0.01). The MC concentration was 2. mu.g/mL and 4. mu.g/mL, respectively, to reduce the TG content in the cells by 38.9% and 34.6%, and the MC concentration was 8. mu.g/mL to reduce the TG content in the cells by 51.3%. Therefore, MC effectively reduced the intracellular TG content of HepG 2.

Example 3 Effect of Monascinol (MC) and Monascin (MS) on the triglyceride content of oleic acid molded HepG2 cells

The experiments were performed as follows:

normal HepG2 cells were obtained first, and HepG2 cells (oleic acid concentration 0.3mmol/L) after oleic acid molding were obtained according to the method of example 1.

Day 1, blank control: HepG2 cells were not treated for normal culture; an oleic acid molding group (the concentration of oleic acid is 0.3mmol/L), and HepG2 cells after the oleic acid molding group are normally cultured without treatment; and MC group: 2 mug/mL Monascine C (MC) is administrated to HepG2 cells after the oleic acid molding; MS group: 2 mu g/mL monascin MS was administered to HepG2 cells after oleic acid molding.

After completion of the administration, the cells of each group were cultured for 24 hours, collected, and the content of triglyceride in HepG2 cells of each group was measured using a triglyceride kit (beijing prilley gene technology ltd), the results of which are shown in fig. 4.

As can be seen from FIG. 4, after 0.3mmol/L oleic acid incubation of HepG2 cells for 24h, TG content in the cells was significantly increased compared to the blank group (P < 0.01). Both MS and MC at the same concentration significantly reduced the TG content in the cells (P < 0.01). The MS and the MC of 2 mu g/mL can respectively reduce the TG content in cells by 26.3 percent and 33.3 percent, and the lipid-lowering effects of the MS and the MC have no significant difference (P is more than 0.01).

Further morphological observation by oil red O staining was carried out, and the results are shown in fig. 5A to 5C (inverted microscope × 400), fig. 5A being a diagram of intracellular lipid accumulation of oleic acid molding HepG 2; FIG. 5B is a graph of intracellular lipid packing in MS group HepG 2; FIG. 5C is a graph showing intracellular lipid accumulation in MC group HepG2, and it can be seen that both the MS group and MC group at 2. mu.g/mL reduced lipid droplets in cells and the color of cells was lighter as compared to the oleic acid model. This is consistent with the detection result of TG.

Example TetraMC inhibits pancreatic lipase Activity and type of inhibition

The experiment used 4-methylumbelliferone oleate (4-MUO) as a substrate, and the inhibitory activity of MC on pancreatic lipase (type II, derived from porcine pancreas) was evaluated by a fluorescence detection method.

The following groups were set up (see also table 1):

blank group: MC-free samples, only substrate, pancrelipase and Tris-HCL buffer;

blank background group: MC sample and pancrelipase were not contained, only substrate and Tris-HCL buffer;

sample background group: no pancrelipase, only MC sample, substrate and Tris-HCL buffer;

sample group: no Tris-HCL buffer was included, only the MC sample, substrate and pancreatic lipase.

TABLE 1 method for in vitro determination of pancreatic lipase activity

The inhibition rate was calculated according to the following formula:

inhibition ratio (%) [ (A)₁–A₂)–(A₃–A₄]/(A₁–A₂)×100；

A₁: blank set fluorescence values; a. the₂: fluorescence values of blank background group

A₃: fluorescence values of the sample set; a. the₄: background group fluorescence values of samples

Each group of substances contained in the ratio shown in Table 1 was added to wells in a black 96-well plate, and each group was set to three in parallel, in which the concentration of 4-MUO was 0.1mM, MC samples were dissolved with DMSO (6 different concentrations: 5, 10, 20, 40, 80, 160. mu.g/mL) and the concentration of lipase solution was 1mg/mL, and after reaction at 25 ℃ for 30min, 100. mu. L0.1M sodium citrate buffer solution was added to terminate the reaction. The lipase can catalyze a substrate 4-methylumbelliferone oleate (4-MUO) to generate a product, namely 4-methylumbelliferone, wherein the fluorescence intensity of the 4-methylumbelliferone is 340nm of an excitation wavelength and 460 nm of an emission wavelength. Through detecting the fluorescence value, the lipase activity is indirectly judged (namely, the higher the lipase activity is, the more 4-methylumbelliferone is catalytically generated, the stronger the fluorescence signal is, therefore, the product 4-methylumbelliferone is measured under the conditions of the excitation wavelength of 360 +/-40 nm and the emission wavelength of 460 +/-40 nm.

When 6 concentrations of the above-mentioned MC were converted into logarithmic concentrations, and then the logarithmic concentrations were plotted on the abscissa and the inhibition ratios were plotted on the ordinate as s-shaped curves shown in fig. 6 in Origin85, it can be seen that the inhibition ratios of the MC against pancreatic lipase increased with the increase in the concentrations. Further, based on the sigmoidal curve, an IC50 value of 75.8 μ g/mL was calculated using software known in the art. The results show that MC has certain inhibitory activity on pancreatic lipase, reduces the intestinal intake of triglyceride by inhibiting the monoglyceride absorption way, and has potential anti-obesity effect.

The inhibition types can be divided into two types, reversible inhibition and irreversible inhibition, according to different binding modes and characteristics of the inhibitor and the enzyme. Irreversible inhibition generally inactivates enzymes by binding groups in the enzyme protein with relatively strong covalent bonds. Reversible inhibition is divided into competitive inhibition, non-competitive inhibition and anti-competitive inhibition. The study reports that the inhibition types of MS and AK on pancreatic lipase are non-competitive inhibition, in the part of experiments, MS and AK are used as controls, the inhibition type of MC is judged by changing the addition sequence of reactants, and the intervention concentrations of three pigment inhibitors are all 80 mug/mL. The results are shown in FIGS. 7A-7C, FIG. 7A is a graph showing the results of inhibition rates of different addition sequences of MS (Monascin ) reactants; FIG. 7B is a graph showing the results of inhibition rates of AK (Ankaflavin ) reactant addition sequences; FIG. 7C is a graph showing the results of inhibition ratios for MC (monascin C, Monascinol) in different addition sequences; it can be seen that the type of suppression of MC is different from that of MS, AK. In FIGS. 7A-7C, S: substrate, I: inhibitor, E: an enzyme.

The type of inhibition of pancreatic lipase by MC is determined from the results of the Lineweaver-burk double reciprocal mapping method as follows. As known in the art, the type of inhibition is non-competitive inhibition if two straight lines intersect at the 1/S axis; if the two straight lines intersect with the 1/V axis, the inhibition type is competitive inhibition; if the two lines are parallel, the inhibition type is an anti-competitive inhibition.

FIG. 8 shows a Lineweaver-Burk curve for MC, where 1/S is the reciprocal substrate concentration; 1/V is the reciprocal of the reaction rate, which is the difference in fluorescence before and after the reaction divided by the difference in time. The basic flow of the experiment for drawing the Lineweaver-Burk curve is as follows: the enzymatic reaction rate was determined at a range of different substrate concentrations at a defined lipase concentration (1 mg/mL). The blank group contained no inhibitor MC (no MC sample, only different concentrations of substrate, pancrelipase and Tris-HCl buffer), the MC group was added (160. mu.g/mLMC, different concentrations of substrate, pancrelipase and Tris-HCl buffer. from FIG. 8, it can be seen that the double reciprocal plot shows that the two lines tend to be parallel, being an anti-competitive inhibition in the reversible inhibition type, indicating that MC does not bind directly to the enzyme, reducing the rate of the catalytic reaction of pancrelipase by binding to the enzyme-substrate complex.

Example five MC animal Experimental data

Animal experiments 24 male Syrian Golden yellow hamster (Golden Syrian hamster, hamster for short) used in animal experiments were purchased from Beijing Wintonlifys laboratory animal technology, Inc., weighing 110-.

After a period of preculture, the cells were randomly divided into 3 groups of 8 cells each, and the groups were divided and tested as follows:

day 1 start daily:

normal group (NOR): freely taking basic feed, and feeding the basic feed to MC group by intragastric administration;

high fat group (HFD), freely ingesting chewable feed with high fat content, and intragastrically administering CMC-Na solution with equivalent amount to MC group;

and MC group: chewable feed with high fat content was ingested freely, and the MC (dissolved in CMC-Na solution) was gavaged at a dose of 20mg/kg body weight.

Hamster body weight, food intake were measured weekly. After 10 weeks, tissue or serum samples were collected and analyzed as follows.

5.1 Effect of MC on hamster weight, liver, kidney and adipose tissue weight

Table 2 records weight indices of organs associated with lipid metabolism, such as hamster liver, kidney, and fat. From the above experimental data, it was found that the MC group significantly suppressed (p < 0.05) weight gain and liver weight gain of hamsters and accumulation of peripheral fat due to high fat diet, compared to the HFD group.

TABLE 2

Group of	NOR	HFD	MC
				Food intake (g)	8.27±0.23^a	7.03±0.24^b	6.71±0.35^b
Weight gain (g)	35.80±4.99^a	53.14±9.02^b	22.33±4.12^c
				Liver weight (g)	4.02±0.20^a	5.57±0.14^b	4.21±0.17^a
Weight of kidney (g)	1.09±0.04^a	1.10±0.05^b	0.97±0.04^a
				Weight of perirenal adipose tissue (g)	1.56±0.33^a	2.94±0.41^b	1.62±0.19^a
Weight (g) of epididymal adipose tissue	2.87±0.37^a	4.87±0.47^b	2.99±0.28^a
				Fat percentage in the perirenal and periepididymal period (%)	2.97±0.37^a	4.79±0.29^b	3.56±0.26^a

5.2 Effect of MC on hamster liver, TG (Triglyceride) and TC (total cholesterol) in serum

TC and TG in the liver are extracted based on a Folch method, and the TC and TG content in the liver tissue is detected by using a TC and TG detection kit produced by Nanjing institute of bioengineering according to the method provided by the instruction.

Collected serum samples were used to measure TC and TG in serum using a Cobas 8000E 602 fully automated biochemical analyzer (roche diagnostics ltd, germany). The results are reported in table 3.

TABLE 3 TC and TG contents in liver and serum

Group of	NOR	HFD	MC
				Serum TG (mmol/L)	1.89±0.23^a	4.38±0.414^b	2.97±0.39^c
Serum TC (mmol/L)	3.81±0.12^a	4.90±0.24^b	4.73±0.21^b
				Hepatic tissue TG (mg/g)	9.63±0.62^a	12.81±0.86^b	9.62±0.34^b
Liver tissue TC (mg/g)	6.53±0.19^a	23.94±1.25^b	20.66±0.58^c

As can be seen from the data in Table 3, TG and TC contents in the liver and serum of hamster in HFD group were significantly increased compared to those in NOR group (p < 0.05). Compared with hamsters in the HFD group, the content of TG and TC in liver and serum of hamsters in the MC group was significantly reduced (p < 0.05), and particularly, the average content of TG in liver of high-fat diet hamsters with MC intervention was the same as that in the NOR group. The result shows that MC has obvious inhibition effect on lipid accumulation in serum and liver caused by high-fat diet, especially has better inhibition effect on TG accumulation in liver and serum, which is consistent with the result that MC inhibits TG accumulation in HepG2 cells in cell experiment.

5.3 hamster liver, adipose tissue pathological section analysis

Fig. 9A to 9C show the results of the liver tissue sections for each hamster under 100 x-ray, and fig. 9A to 9C show the results of the liver tissue sections for each hamster under 400 x-ray, wherein fig. 9A and 9A are NOR groups, fig. 9B and 9B are HFD groups, and fig. 9C and 9C are MC groups. It can be seen that lipid accumulation was significantly reduced in the cells of the MC group and the hepatocyte cords tended to be normal, compared to the hepatocytes of the HFD group, which were enlarged due to lipid accumulation.

Fig. 10A to 10C show the results of the examination of adipose tissue sections of hamsters for each group under a 100 x-ray microscope, and fig. 10A to 10C show the results of the examination of adipose tissue sections of hamsters for each group under a 400 x-ray microscope, in which fig. 10A and 10A are NOR groups, fig. 10B and 10B are HFD groups, and fig. 10C and 10C are MC groups. It can be seen that the cells in epididymal and perirenal adipose tissues in the HFD group had significantly increased volumes compared to the NOR group, while the cells in the MC group had significantly decreased volumes compared to the HFD group, which was between the volumes of the cells in the NOR and HFD groups.

By combining the above cell experiments, in vitro enzyme experiments and animal experiments, MC can effectively prevent weight gain, peripheral fat accumulation, and accumulation of TC and TG in blood and liver caused by high fat diet. Can be used for preventing and treating lipid metabolism disorder caused by obesity and its related metabolic syndrome (such as non-alcoholic fatty liver, diabetes, asthma, osteoarthritis, etc.).

EXAMPLE six preparation of Monascus purpureus went C Using Monascus purpureus provided by the present invention

The monascus is a monascus preserved in China general microbiological culture Collection center (CGMCC for short) in 2019, 9 and 20 months and has the preservation number of CGMCC No. 18578. The raw material is rice which is commonly purchased and obtained, and all components in the culture medium are reagents which are conventional in the field and can be purchased commercially.

Firstly, monascin C is prepared by utilizing monascus CGMCC No.18578, and the method comprises the following steps:

1) soaking rice and water at a mass-to-volume ratio (kg/L) of 1:1 at room temperature for 4-24h, draining water, placing into a culture bottle, and sterilizing at 121 deg.C and 0.1MPa for 20min to obtain solid fermentation culture medium;

2) inoculating Monascus ruber CGMCC No.18578 stored in 4 deg.C refrigerator into fresh wort slant culture medium, and culturing at 30 deg.C for 48 hr to activate the Monascus ruber; and pouring sterilized sterile water into the activated strain inclined plane under the aseptic operation, scraping spores off an inoculating ring to prepare a spore suspension, transferring the spore suspension into a seed liquid culture medium, and carrying out shaking culture at the constant temperature of 180r/min at 30 ℃ for 36h to obtain the seed liquid of the monascus purpureus.

Wherein the slant culture medium for activation is prepared by slightly pulverizing barley malt, weighing 250.0g, adding 1L water, heating in 60 deg.C constant temperature water bath for 4 hr, filtering, adding water, diluting to 12 ° Brix, adding 3.0g agar, and sterilizing at 121 deg.C and 0.1MPa for 20 min.

The seed liquid culture medium is prepared by passing 6.0g of glucose, 2.0g of peptone and 1.0g of NaNO₃、1.0 gKH₂PO₄、0.5gMgSO₄Dissolving in 100mL water, packaging into 250mL conical flask, sealing with 8 layers of gauze and kraft paper, and sterilizing at 121 deg.C and 0.1MPa for 20 min.

3) Filtering the monascus seed solution by using double-layer gauze to remove mycelia, and mixing the monascus seed solution without the mycelia according to the ratio of 1: injecting into the solid fermentation culture medium at a volume/weight ratio of 5-10L/kg, and fermenting at 30 deg.C for 20 days to obtain fermented rice, i.e. red yeast rice;

4) drying and crushing the fermented red yeast rice in an oven at 60 ℃, extracting by using 70% ethanol, wherein the weight ratio of the red yeast rice to the ethanol is 1: 5-20, and separating the extracting solution by high performance liquid chromatography to obtain the monascin C.

Second, MC structure analysis prepared from Monascus ruber CGMCC No.18578

The results of ESI-MS measurement of monascin C obtained are shown in FIG. 11, which has a primary positive ion peak M/z of 361.2000[ M + H ]]⁺The compound has a molecular formula of C₂₁H₂₈O₅. Process for preparing monascin C¹H-NMR results are shown in FIG. 12, for monascin C¹³The results of C-NMR are shown in FIG. 13 and are the same as the structural characterization information of Monascinol described in JP 2008-56618A.

Third, MC content determination prepared from Monascus ruber CGMCC No.18578

Drawing an MC standard curve:

preparation of purified MC (HPLC purity)>95%) dissolved in 70% ethanolPreparing 4mg/ml mother solution, obtaining MC standard working solution with the concentration of 400, 200, 100, 50 and 25 mu g/ml respectively by gradient dilution, drawing a standard curve by 1260 type HPLC detection of Agilent technologies, Inc. of America, and carrying out HPLC conditions: column ZORBAX Eclipse Plus C18(5 μm, 4.6X 250 mm); mobile phase acetonitrile-0.1% formic acid water 60:40(V/V), isocratic elution; a diode array detector; the detection wavelength is 390 nm; the column temperature is 25 ℃; the flow rate is 1 mL/min; the sample was 20. mu.L. Linear regression is carried out on the concentration X by the peak area Y to obtain the MC regression equation of Y being 31.63X +122, R²＝0.998。

Measuring the MC content in the red yeast rice fermentation product:

drying the fermentation product (namely the fermented red yeast rice) at 60 ℃, grinding and sieving (200 meshes), accurately weighing 0.50g of the fermentation product into a 10mL centrifuge tube, carrying out ultrasonic extraction on 70% ethanol solution with the material-liquid ratio of 1:20 for 30min, centrifuging at 3500r/min for 10min, properly diluting the supernatant, filtering the extract into a liquid phase vial through a 0.22 mu m organic filter, and carrying out HPLC detection. And calculating to obtain the MC content of 8mg/g in the fermentation product according to the MC peak area detected in the sample, the sample dilution times and the MC standard curve. The content of the MC is far higher than that of the MC (0.31mg/g) in the red yeast rice fermented by the monascus used in the invention patent TW1437001B in Taiwan. The Monascus CGMCC No.18578 fermented MC-rich red yeast product such as fermented red yeast rice can be used for developing functional food for regulating lipid metabolism disorder and used as raw material of medicine.

Claims

1. Application of monascin C in preparing fat reducing product is provided.

2. Use according to claim 1, wherein the fat-reducing preparation is a fat-reducing functional food.

3. Use according to claim 2, wherein the lipid-reducing functional food is for preventing or improving the sub-health status associated with obesity in an individual.

4. The use of claim 1, wherein the lipid-reducing preparation is a lipid-reducing pharmaceutical product.

5. The use according to claim 4, wherein the lipid-lowering drug is for the prevention or treatment of a disease associated with abnormal lipid metabolism in an individual.

6. The use of claim 5, wherein the disorder associated with abnormal lipid metabolism in the subject comprises one or more of nonalcoholic fatty liver disease, cardiovascular disease, diabetes, and asthma.

7. The use of claim 4, wherein the lipid-lowering drug is formulated in the form of hard gelatin capsules, soft gelatin capsules, tablets, granules, powders, oral liquids, or injections.

8. The use according to claim 4 or 5, wherein the lipid-lowering drug is a unit formulation.

9. The use according to claim 8, wherein said unit formulation comprises from 50 to 200mg monascin C.